Celularity Inc (CELU) — SEC Financial Statements & Analysis

Celularity Inc (CELU) is a pharmaceutical preparations company, incorporated in DE. Celularity Inc trades on Nasdaq as: CELU. Celularity Inc (CELU)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-09-29. Based on that filing, Celularity Inc carries a market cap of $38.66M, a P/E ratio of -0.54x, a P/B ratio of -1.10x, a P/S ratio of 2.04x, an enterprise value of $28.18M, and an EV/EBITDA multiple of -0.51x. On profitability, it posts a gross margin of 5.26%, an operating margin of -321.32%, a net margin of -375.18%, a Return on Equity (ROE) of 349.16%, a Return on Assets (ROA) of -62.33%, and a Return on Invested Capital (ROIC) of -84.38%. Per share, it reports EPS of $-2.45, diluted EPS of $-2.35, free cash flow per share of $-0.30, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -62.78% year-over-year, net income growth of 27.93% year-over-year, and EPS growth of 3.56% year-over-year. On the balance sheet, it maintains a current ratio of 0.09x, a quick ratio of 0.07x, working capital of $-64.28M, a debt-to-equity ratio of -3.82x, a debt ratio of 1.35, free cash flow of $-8.81M (TTM), and net debt of $-10.48M. Figures sourced from SEC EDGAR.

Market Cap

$38.66M

P/E TTM

-0.54x

EPS TTM

$-2.45

P/B TTM

-1.10x

ROE TTM

349.16%

ROA TTM

-62.33%

Debt To Equity

-3.82x

Free Cash Flow TTM

$-8.81M

Net Revenue TTM Growth 1Y

-62.78%

Data as of 2026-03-31 · Source: SEC EDGAR